Dabigatran: Do we have sufficient data?

Archives of Internal Medicine

Volumn 172, Issue 5, 2012, Pages 403-404

  Jacobs, Jeremy M ^a,b   Stessman, Jochanan ^a,b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; DABIGATRAN ETEXILATE; ENOXAPARIN; PLACEBO; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BODY WEIGHT; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ELECTROCARDIOGRAM; EMBOLISM; FOOD AND DRUG ADMINISTRATION; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; KIDNEY DISEASE; META ANALYSIS (TOPIC); NOTE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; STROKE; SYSTEMATIC REVIEW; THROMBOSIS PREVENTION; THROMBUS; VENOUS THROMBOEMBOLISM;

ACUTE CORONARY SYNDROME; BENZIMIDAZOLES; BETA-ALANINE; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; THROMBOEMBOLISM;

EID: 84857963926     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2011.1721     Document Type: Note

References (10)

1. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials [published online January 9, 2012]. Arch Intern Med. 2012;172(5):397-402.
2. Connolly SJ, Ezekowitz MD, Yusuf S, et al RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation [published correction appears in N Engl J Med. 2010;363(19):1877]. N Engl J Med. 2009;361(12):1139-1151.
3. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L; Randomized Evaluation of Longterm Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363(19):1875-1876.
4. Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med. 2009;169(19):1756-1761.
5. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252-260.
6. Ioannidis JPA. Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials? Philos Ethics Humanit Med. 2008;3:14. doi:10.1186/1747-5341-3-14.
7. Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011;123(20):2226-2235.
8. Hernandez AV, Walker E, Ioannidis JPA, Kattan MW. Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone. Am Heart J. 2008;156(1):23-30.
9. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009;32(1):19-31.
10. Steinman MA, Handler SM, Gurwitz JH, Schiff GD, Covinsky KE. Beyond the prescription: medication monitoring and adverse drug events in older adults. J Am Geriatr Soc. 2011;59 (8):1513-1520.